



www.veteransmates.net.au



Veterans' MATES Response Form Pharmacist

Accredited Continuing Professional Development credits are available to participants submitting this response form. Activity requirements are available in the attached flyer or at www.veteransmates.net.au. Additional copies of the response form are available to download from www.veteransmates.net.au

Please include your Australian Health Practitioner Registration Number in the appropriate box on the bottom of the questionnaire. We are required to maintain a record of participating pharmacists for audit purposes. You are required to self-record details of this CPD activity.

Details for your activity record

Activity title: *Veterans' MATES May 2023*

Provider: *DVA*

Type of activity: *Therapeutic brief*

CPD Credits: *1 CPD credit (Group 1)*

Topic: *Diabetes Medicines*

Accreditation number: *CX22021C*


After reading the therapeutic brief you should be able to:

- *identify which patients with type 2 diabetes might benefit from having a SGLT2 inhibitor or a GLP-1 analogue added to their medicine regimen*
- *assist veterans with diabetes in understanding when to talk to their GP about their diabetes management*
- *conduct a Home Medicines Review (HMR) or Residential Medication Management Review (RMMR) for veterans with diabetes.*

Competency Standards (2016) addressed: 1.1.2, 1.4.2, 1.4.3, 1.5.1, 1.6.1, 1.6.2, 1.6.3, 2.1.1, 2.1.2, 2.1.3, 2.1.4, 2.2.1, 2.2.2, 2.2.3, 2.3.1, 2.3.2, 3.1.1, 3.1.2, 3.1.3, 3.2.2, 3.2.3, 3.2.5, 3.2.6, 3.3.1, 3.3.2, 3.3.3, 3.5.1, 3.5.2, 3.6.1, 4.1.2, 5.1.3, 5.2.2, 5.2.3, 5.2.4, 5.3.1, 5.3.2, 5.3.3, 5.3.4.



University of
South Australia

 Veterans' MATES

Provided by: University of South Australia | Quality Use of Medicines and Pharmacy Research Centre

In association with: Discipline of General Practice, The University of Adelaide |

School of Public Health, The University of Adelaide | NPS MedicineWise |

Australian Medicines Handbook | Drug and Therapeutics Information Service

VMHPR_0918



Australian Government

Department of Veterans' Affairs

Veterans' MATES

Reducing the impact of cardiovascular and renal disease in type 2 diabetes: what medicines and when? (May 2023)

Please place a cross in the appropriate box using a black or blue pen.
Mark one box only for each question.

1. How useful have you found the therapeutic brief?

Very useful Moderately useful Slightly useful Not at all useful

2. Prior to reading the therapeutic brief, were you aware that cardiovascular disease is the leading cause of death in people with diabetes?

Yes No

3. Prior to reading the therapeutic brief, were you aware that adding a SGLT2 inhibitor or a GLP-1 analogue can provide extra benefit in protecting against cardiovascular and renal disease?

Very aware Moderately aware Slightly aware Not at all aware

4. How likely are you to suggest a Medicines Review (either HMR or RMMR) for your patients who have type 2 diabetes?

Very likely Moderately likely Slightly likely Not at all likely

5. To what degree will the information in the therapeutic brief assist you in conducting a Medicines Review (HMR or RMMR) for your DVA patients with type 2 diabetes?

A lot Somewhat A little Not at all

I do not conduct Medicine Reviews

6. When conducting a Medicines Review for a patient with type 2 diabetes, how likely are you to consider whether they might benefit from the addition of a SGLT2 inhibitor or a GLP-1 analogue to provide extra benefit against cardiovascular and renal disease?

Very likely Moderately likely Slightly likely Not at all likely

7. The veteran brochure includes information about services to help DVA patients better manage their diabetes. How likely are you to use this brochure when talking to your patients about the services and supports that might be available to them?

Very likely Moderately likely Slightly likely Not at all likely

8. DVA Gold Card holders with diabetes may be eligible for the Coordinated Veterans' Care (CVC) program if they are living at home and are at risk of unplanned hospital admissions. How likely are you to encourage your veteran patients to talk to their GP about participating in the CVC program?

Very likely Moderately likely Slightly likely Not at all likely

9. After reading the therapeutic brief, how likely are you to initiate an educational session at an aged-care facility about the potential benefits of using a SGLT2 inhibitor or a GLP-1 analogue for protecting against cardiovascular and renal disease in type 2 diabetes?

Very likely Moderately likely Slightly likely Not at all likely

I do not provide a service for aged-care facility

For your CPD please provide your
Australian Health Practitioner Registration Number

P H A



Thank you for your support.

Please return to:

Veterans' MATES Reply Paid 85230 MARLESTON DC SA 5033.